Cyclophosphamide (generic), Cytoxan Newswire (Page 8)

Cyclophosphamide (generic), Cytoxan Newswire (Page 8)

Comprehensive Real-Time News Feed for Cyclophosphamide (generic), Cytoxan. (Page 8)

Results 141 - 160 of 642 in Cyclophosphamide (generic), Cytoxan

  1. Baxter International Inc (BAX) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Apr 7, 2017 | IntersportsWire

    According to Zacks, "Baxter reported mixed results for the fourth quarter of 2016, wherein adjusted earnings beat the Zacks Consensus Estimate while revenues missed the same. Over the past one year, the company outperformed the broader industry in terms of price movement.

    Comment?

  2. Baxter International Inc (BAX) Downgraded by Zacks Investment Research to "Sell"Read the original story w/Photo

    Apr 6, 2017 | Daily Political

    According to Zacks, "Baxter reported mixed results for the fourth quarter of 2016, wherein adjusted earnings beat the Zacks Consensus Estimate while revenues missed the same. Over the past one year, the company outperformed the broader industry in terms of price movement.

    Comment?

  3. Zacks Investment Research Downgrades Baxter International Inc (BAX) to SellRead the original story w/Photo

    Apr 5, 2017 | AmericanBankingNews.com

    According to Zacks, "Baxter reported mixed results for the fourth quarter of 2016, wherein adjusted earnings beat the Zacks Consensus Estimate while revenues missed the same. Over the past one year, the company outperformed the broader industry in terms of price movement.

    Comment?

  4. Lupus Nephritis Market - Global Industry Analysis, Size, Share,...Read the original story w/Photo

    Apr 5, 2017 | SBWire

    Report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size.

    Comment?

  5. Lupus Nephritis Market (2016 - 2023) : Key Trends, Industry...Read the original story w/Photo

    Apr 5, 2017 | SBWire

    Global Lupus Nephritis Market Lupus nephritis refers to the kidney damage caused by the disease lupus erythematosus. Lupus erythematosus is an autoimmune disease where the immune system turns against the body, affecting vital organs.

    Comment?

  6. Investment Analysts' Downgrades for April, 5th (BAX, BLL, BOKF,...Read the original story w/Photo

    Apr 5, 2017 | AmericanBankingNews.com

    According to Zacks, "Baxter reported mixed results for the fourth quarter of 2016, wherein adjusted earnings beat the Zacks Consensus Estimate while revenues missed the same. Over the past one year, the company outperformed the broader industry in terms of price movement.

    Comment?

  7. Corbus To Commence Single Phase III Study Of Anabasum For Treatment...Read the original story

    Apr 4, 2017 | BioSpace

    The U.S. Food and Drug Administration has provided guidance on the development program and the design of the study. The international Phase 3 trial will be a double-blind, randomized, placebo-controlled study conducted in approximately 270 adults with systemic sclerosis.

    Comment?

  8. Immunovaccine Inc. Presents Preclinical Research at AACR 2017 on...Read the original story

    Apr 5, 2017 | World News Report

    Study Part of Ongoing Effort to Identify Novel Combinations of DepoVax -based Immuno-oncology Candidates to Improve the Responses of Other Novel Immunotherapy Agents Immunovaccine Inc. , a clinical stage immuno-oncology company, announced that new preclinical data presented at the 2017 American Association for Cancer Research Annual Meeting demonstrated that phosphatidylserine targeting antibodies can enhance the anti-cancer activity of its DepoVaxa -based therapeutic vaccine platform. In the study, researchers combined a Peregrine Pharmaceuticals' PS-targeting antibody compound with a DepoVaxa -based HPV16 peptide vaccine and metronomic cyclophosphamide .

    Comment?

  9. Spectrum Pharmaceuticals Highlights Preclinical Data of ROLONTISa ...Read the original story

    Apr 4, 2017 | Customer Interaction Solutions

    Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the presentation of preclinical data of ROLONTIS from a poster presentation session at the American Association for Cancer Research Annual Meeting. "We are excited to see positive data continuing to develop in our highest priority program," said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

    Comment?

  10. Spectrum Pharma Highlights Preclinical Data Of ROLONTIS (Eflapegrastim) At The AACR Annual MeetingRead the original story

    Apr 3, 2017 | BioSpace

    Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced the presentation of preclinical data of ROLONTIS from a poster presentation session at the American Association for Cancer Research Annual Meeting. "We are excited to see positive data continuing to develop in our highest priority program," said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

    Comment?

  11. Genome-wide association study of chemotherapeutic agent-induced...Read the original story

    Apr 1, 2017 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Chemotherapeutic agents are notoriously known to have a narrow therapeutic range that often results in life-threatening toxicity.

    Comment?

  12. Successful adoptive transfer and in vivo expansion of human...Read the original story

    Mar 31, 2017 | CiteULike

    We previously demonstrated that autologous natural killer -cell therapy after hematopoietic cell transplantation is safe but does not provide an antitumor effect. We hypothesize that this is due to a lack of NK-cell inhibitory receptor mismatching with autologous tumor cells, which may be overcome by allogeneic NK-cell infusions.

    Comment?

  13. Immunovaccine Announces 2016 Year-End ResultsRead the original story w/Photo

    Mar 30, 2017 | Market Wire

    Immunovaccine Inc. , a clinical stage vaccine and immunotherapy company, today announced its financial and operational results for the year ended December 31, 2016. "In 2016, our company continued to leverage the competitive advantage provided by our proprietary DepoVax technology," said Frederic Ors, Chief Executive Officer at Immunovaccine.

    Comment?

  14. Global Multiple Myeloma Therapeutics Market Size and Forecast Report 2021Read the original story

    Mar 30, 2017 | Emailwire.com

    Multiple Myeloma Therapeutics Market by Treatment Type, Drug Type and Region - Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts According to the report Multiple Myeloma Therapeutics Market , published by Market Data Forecast, the global market is projected to reach USD 9.1 Billion by 2021, at a CAGR of 4.8% from 2016 to 2021. For full report refer to Multiple myeloma remains comparatively rare, it is a deceptive disease and patients typically deplete treatment alternatives.

    Comment?

  15. ANCA vasculitis in a patient with Alport syndrome: a difficult diagnosis but a treatable diseaseRead the original story w/Photo

    Mar 28, 2017 | BioMed Central

    Alport syndrome and ANCA-associated vasculitis are both rare diseases. The co-existence of these two conditions has never been reported.

    Comment?

  16. Immunovaccine Announces Positive Interim Clinical Data from Ovarian...Read the original story w/Photo

    Mar 29, 2017 | Market Wire

    Immunovaccine Inc. , a clinical stage vaccine and immunotherapy company, today announced the first interim data analysis from its ongoing Phase 1b clinical study of its novel T-cell activating immuno-oncology candidate, DPX-Survivac, in combination with epacadostat and low-dose cyclophosphamide. The analysis included the results of blood tests, tumor biopsies and CT scans to assess safety, disease progression and T-cell response for the first four evaluable patients in the trial.

    Comment?

  17. Kiadis Pharma To Present Information On The Design Of Its Phase III...Read the original story

    Mar 15, 2017 | BioSpace

    In addition, Kiadis Pharma will host a satellite symposium on March 26, 2017 entitled: "Advances in Haploidentical Stem Cell Transplantation and Post-Transplant Immunotherapy". The symposium will be chaired by Dr. Hermann Einsele, Professor at the University Hospital of the Julius-Maximilians-University, WA1 4rzburg, Germany and he will be joined by several other international key opinion leaders in the field of hematopoietic stem cell transplantation.

    Comment?

  18. Kite Pharma Highlights Publication From NCI Demonstrating Durable...Read the original story

    Mar 14, 2017 | BioSpace

    Kite Pharma, Inc. today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute study of anti-CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma . The research, led by James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI Center for Cancer Research, was performed pursuant to a CRADA between NCI and Kite.

    Comment?

  19. TapImmune Provides Year End 2016 Corporate and Clinical UpdateRead the original story

    Mar 14, 2017 | BioSpace

    Completed first safety cohort in Memorial Sloan Kettering-sponsored Phase 2 combination study with AstraZeneca's durvalumab in platinum-resistant ovarian cancer; now more than 50% enrolled Announced second U.S. Dept. of Defense-funded Phase 2 breast cancer study; Mayo Clinic to vaccinate women with ductal carcinoma in situ using HER2-targeted T-cell vaccine TapImmune, Inc. , a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today provided its first quarterly business update, following the company's uplisting to The NASDAQ Capital Market in the fourth quarter 2016.

    Comment?

  20. Kite Pharma Highlights Publication from the National Cancer Institute ...Read the original story

    Mar 14, 2017 | Customer Interaction Solutions

    Kite Pharma Highlights Publication from the National Cancer Institute Demonstrating Durable Complete Remissions in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy and Anti-CD19 CAR T-Cell Therapy Kite Pharma, Inc. today highlighted the publication of results in the Journal of Clinical Oncology from a National Cancer Institute study of anti-CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory non-Hodgkin lymphoma . The research, led by James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI Center for Cancer Research, was performed pursuant to a CRADA between NCI and Kite.

    Comment?